Alnylam Pharmaceuticals Net Profit Margin 2006-2021 | ALNY

Current and historical net profit margin for Alnylam Pharmaceuticals (ALNY) from 2006 to 2021. Net profit margin can be defined as net Income as a portion of total sales revenue. Alnylam Pharmaceuticals net profit margin for the three months ending September 30, 2021 was .
Alnylam Pharmaceuticals Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2021-09-30 $0.75B $-0.84B -111.72%
2021-06-30 $0.69B $-0.89B -128.74%
2021-03-31 $0.57B $-0.88B -153.15%
2020-12-31 $0.49B $-0.86B -174.04%
2020-09-30 $0.40B $-0.89B -221.95%
2020-06-30 $0.35B $-0.85B -245.22%
2020-03-31 $0.29B $-0.89B -309.79%
2019-12-31 $0.22B $-0.89B -402.73%
2019-09-30 $0.17B $-0.82B -485.80%
2019-06-30 $0.10B $-0.86B -848.51%
2019-03-31 $0.09B $-0.80B -932.56%
2018-12-31 $0.08B $-0.76B -1014.67%
2018-09-30 $0.09B $-0.69B -752.17%
2018-06-30 $0.11B $-0.57B -532.71%
2018-03-31 $0.09B $-0.52B -563.44%
2017-12-31 $0.09B $-0.49B -544.44%
2017-09-30 $0.07B $-0.46B -668.12%
2017-06-30 $0.07B $-0.44B -669.70%
2017-03-31 $0.06B $-0.41B -701.69%
2016-12-31 $0.05B $-0.41B -872.34%
2016-09-30 $0.04B $-0.39B -1021.05%
2016-06-30 $0.03B $-0.36B -1203.33%
2016-03-31 $0.03B $-0.34B -1143.33%
2015-12-31 $0.04B $-0.29B -692.86%
2015-09-30 $0.06B $-0.22B -381.03%
2015-06-30 $0.06B $-0.19B -298.41%
2015-03-31 $0.06B $-0.16B -262.30%
2014-12-31 $0.05B $-0.36B -720.00%
2014-09-30 $0.04B $-0.37B -1002.70%
2014-06-30 $0.04B $-0.36B -1020.00%
2014-03-31 $0.04B $-0.33B -894.59%
2013-12-31 $0.05B $-0.09B -185.42%
2013-09-30 $0.05B $-0.12B -264.44%
2013-06-30 $0.05B $-0.11B -205.66%
2013-03-31 $0.07B $-0.10B -160.00%
2012-12-31 $0.07B $-0.11B -158.21%
2012-09-30 $0.08B $-0.06B -73.42%
2012-06-30 $0.08B $-0.05B -61.45%
2012-03-31 $0.08B $-0.05B -62.65%
2011-12-31 $0.08B $-0.06B -68.67%
2011-09-30 $0.08B $-0.05B -59.52%
2011-06-30 $0.09B $-0.05B -51.65%
2011-03-31 $0.10B $-0.05B -49.48%
2010-12-31 $0.10B $-0.04B -43.56%
2010-09-30 $0.11B $-0.05B -42.06%
2010-06-30 $0.10B $-0.04B -42.72%
2010-03-31 $0.10B $-0.05B -51.49%
2009-12-31 $0.10B $-0.05B -47.52%
2009-09-30 $0.10B $-0.05B -50.00%
2009-06-30 $0.10B $-0.04B -43.00%
2009-03-31 $0.10B $-0.03B -33.33%
2008-12-31 $0.10B $-0.03B -27.08%
2008-09-30 $0.09B $-0.02B -16.67%
2008-06-30 $0.08B $-0.07B -81.25%
2008-03-31 $0.07B $-0.07B -100.00%
2007-12-31 $0.05B $-0.09B -172.00%
2007-09-30 $0.04B $-0.08B -207.69%
2007-06-30 $0.03B $-0.04B -112.90%
2007-03-31 $0.03B $-0.03B -114.29%
2006-12-31 $0.03B $-0.02B -70.37%
2006-09-30 $0.02B $-0.04B -181.82%
2006-06-30 $0.02B $-0.04B -293.33%
2006-03-31 $0.01B $-0.05B -450.00%
2005-12-31 $0.01B $-0.04B -716.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $22.548B $0.493B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09